Streetbeat News

EFTR

eFFECTOR Therapeutics Inc

http://effector.com/

CEO

Steve Worland

Industry

Research and Development in Biotechnology (except Nanobiotechnology)

effector therapeutics is a biotechnology company located in 11180 roselle street, san diego, ca, united states.

Open

0.00

Mkt cap

941

Volume

202K

High

0.00

P/E Ratio

N/A

52-wk high

17.90

Low

0.00

Div yield

N/A

52-wk low

0.00

U.S. stocks declined with the Dow Jones falling over 200 points. RPM International's shares dropped after Q3 results, showing a slight sales increase but beating EPS estimates. TCBP, ALUR, and CADL shares surged on positive news, while EFTR, ACHL, and KWE shares plummeted due to disappointing updates. Oil and gold prices rose.

Portfolio Pulse from Avi Kapoor

April 04, 2024 | 6:39 pm

Health care stocks experienced significant movements in Thursday's intraday session. Candel Therapeutics, TC BioPharm, Eiger BioPharmaceuticals, Macrogenics, Barinthus Biotherapeutics, and Curis saw notable gains, with increases ranging from 24.62% to 64.3%. Conversely, eFFECTOR Therapeutics, Achilles Therapeutics, Inotiv, Universe Pharmaceuticals, Kintara Therapeutics, and Carmell faced declines, with decreases ranging from 12.85% to 80.2%. The movements were attributed to various factors, including earnings releases and market dynamics.

Portfolio Pulse from Benzinga Insights

April 04, 2024 | 4:31 pm

Nasdaq rose 1% with ConAgra Brands reporting better-than-expected Q3 earnings, leading to a positive market sentiment. Real estate and healthcare sectors saw gains, while TC Biopharm, Allurion Technologies, and Candel Therapeutics experienced significant stock increases. Conversely, eFFECTOR Therapeutics, Achilles Therapeutics, and KWESST Micro Systems saw notable declines. Oil prices slightly dropped, while gold and silver prices increased.

Portfolio Pulse from Avi Kapoor

April 04, 2024 | 3:58 pm

eFFECTOR Therapeutics Inc (EFTR) announced disappointing results from the Phase 2 KICKSTART trial of tomivosertib in combination with Merck & Co Inc's (MRK) Keytruda for non-small cell lung cancer, failing to meet the primary endpoint. The company will discontinue the development of tomivosertib for this indication but plans to focus on developing Zotatifin for breast cancer and continue a trial of tomivosertib in AML. EFTR shares dropped 78.1% to $3.6.

Portfolio Pulse from Vandana Singh

April 04, 2024 | 2:38 pm

U.S. stocks traded higher with the Dow Jones gaining over 100 points. Real estate shares led gains, while U.S. jobless claims rose to 221,000. TCBP surged 118% after announcing a letter of intent for an acquisition. ALUR jumped 61% following the commercial availability of its Virtual Care Suite and a positive analyst rating. TVGN gained 55% after a new executive appointment. EFTR, KYCH, and KWE saw significant drops due to various company-specific news.

Portfolio Pulse from Avi Kapoor

April 04, 2024 | 2:02 pm

EFFECTOR Therapeutics shares have resumed trading, indicating a potential shift in market dynamics for the company.

Portfolio Pulse from Benzinga Newsdesk

April 04, 2024 | 1:52 pm

EFFECTOR Therapeutics shares were halted due to a circuit breaker triggered by a significant drop, with the stock now down 83.2%.

Portfolio Pulse from Benzinga Newsdesk

April 04, 2024 | 1:49 pm

EFFECTOR Therapeutics announced the primary analysis results of the Phase 2 KICKSTART trial of tomivosertib combined with pembrolizumab in non-small cell lung cancer, leading to a decrease in their share prices.

Portfolio Pulse from Benzinga Newsdesk

April 04, 2024 | 1:17 pm

Trading for EFTR was halted and then resumed at 8:55:00 AM ET, with updates on quotation resumption, news, and resumption times provided.

Portfolio Pulse from Benzinga Newsdesk

April 04, 2024 | 12:55 pm

Trading for EFTR was halted at 8:25:00 a.m. ET due to pending news. The halt is a temporary measure until the news affecting the company is released.

Portfolio Pulse from Benzinga Newsdesk

April 04, 2024 | 12:25 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.